Drug-induced perturbations in the in vivo distribution of oncological radiotracers--I. 5-Fluoro-6-3H-2'-deoxyuridine influenced by nitrobenzylthioinosine 5'-phosphate (NBMPR-P).
Nitrobenzylthioinosine 5'-monophosphate (NBMPR-P), a water-soluble form of the nucleoside transport inhibitor nitrobenzylthioinosine (NBMPR) was administered by i.v. injection to normal mice and BDF1 mice with implanted Lewis Lung carcinomas. Tritiated 5-Fluoro-2'-deoxyuridine (3H-FUdR) was injected either alone (control), 10 min before (I + 10), 10 min (I - 10) after, 60 min (I - 60) after, or simultaneously (I = 0) with the transport inhibitor. Tissue distributions of tritium were determined after intervals of 1, 2 and 4 h. The per cent of injected radioactivity (% dose) in liver was increased by all NBMPR-P protocols. Kidney radioactivity was similarly affected, with maximum increases (from 9.3 +/- 3.4 to 24.1 +/- 5.2% of the injected dose/g) after 1 h in the I - 60 animals. No statistically significant changes in the distribution of radioactivity in tumor, spleen, marrow or blood were induced by doses of NBMPR-P. Elevated levels of tritium radioactivity in blood were accompanied by similar increases in renal and hepatic radioactivity. The apparent increase in the tumor uptake of 3H-FUdR (from 1.4 +/- 0.2 to 5.7 +/- 2.3% dose/g) was not statistically significant at the 95% confidence limit. In general, NBMPR-P induced a relative tumor-sparing effect and at the same time increased uptake of 3H-FUdR by the liver and kidney, or delayed its clearance from these organs. There was no evidence to suggest that any advantage would be gained by using NBMPR-P treatment in conjunction with radiolabelled FUdR for tumor diagnosis.(ABSTRACT TRUNCATED AT 250 WORDS)
D000818:Animals; D005467:Floxuridine / Q000378:metabolism*; D007288:Inosine / Q000031:analogs & derivatives*; D008175:Lung Neoplasms / Q000000981:diagnostic imaging*; D008297:Male; D051379:Mice; D008815:Mice, Inbred Strains; D009368:Neoplasm Transplantation; D011877:Radionuclide Imaging; D013868:Thioinosine / Q000031:analogs & derivatives* / Q000494:pharmacology; D013873:Thionucleotides / Q000494:pharmacology*; D014018:Tissue Distribution; D014316:Tritium / Q000378:metabolism*
D013873:Thionucleotides; D005467:Floxuridine; D014316:Tritium; D013868:Thioinosine; D007288:Inosine; C028318:nitrobenzylthioinosine 5'-monophosphate